Disclosure of the role of CCR1 and CCR2 in the pathogenesis of CLL could suggest these receptors and their signaling pathways as targets for the development of anti-progression therapeutics in CLL. Here, CCR1 is linked to B-cell chronic lymphocytic leukemia.